Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
Cascade testing of relatives has been shown to be feasible, acceptable and cost-effective in the UK, but requires a supply of index cases. Feasibility of universal screening at age 1-2 years was also recently demonstrated. This paper examines whether this would be a cost-effective adjunct to Cascade testing, given the current and plausible future undiaganosed FH prevalence.
Source: Atherosclerosis
Related stories
- Saving the PASS system for the sake of England’s FH Services, for current and future generations
- The national Child Parent Screening Service (CPSS) pilot has been extended until October 2024
- Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis
- how the NHS is working to deliver improved lipid management
- HEART UK 36th Annual Medical and Scientific Conference 2023 LIPIDS – THE BEST YET - CONFERENCE REVIEW
- Our new Lipidology Podcast
- Recently formed Lipoprotein(a) Taskforce publishes Call to Action to increase recognition and acceptance of Lp(a) as an ASCVD risk factor
- Lipoprotein (a) disorder gets SNOMED codes
- Would you like to update your knowledge of lipid management and have the opportunity to liaise with others working in this area?
- Familial Hypercholesterolaemia Gene Testing One-Day Online Workshop - Dates for 2023